Pharma's next cash cows could be specialized treatments

Pharmaceutical companies, facing a patent cliff with over $500 billion in brand-name sales at risk from generic competition by 2032, are pivoting to specialized treatments tailored to patients' genes and lifestyles. The shift toward precision medicine could reshape which diseases are prioritized and how the health system pays for care, with a new report highlighting the chase for blockbuster specialty drugs.